| Literature DB >> 33097042 |
Jie Pei1,2, Lin Xiong1,2, Min Chu1,2, Xian Guo3,4, Ping Yan5,6.
Abstract
BACKGROUND: Lactoferricin (Lfcin) is an antimicrobial activity center of lactoferrin, produced by hydrolysis from the N-terminal of lactoferrin. It was hypothesized that the intramolecular disulfide bond in Lfcin could affect its antibacterial function through influencing its molecular structure. To prove this hypothesis, bovine Lfcin (bLfcin) and its two derivatives, bLfcin with an intramolecular disulfate bond (bLfcin DB) and bLfcin with a mutation C36G (bLfcin C36G), were synthesized, purified, and identified. The circular dichroism spectra of the peptides were detected in solutions with different ionic and hydrophobic strength. The antibacterial activity of the peptides against Trueperella pyogenes, separated from cow milk with mastitis, were determined.Entities:
Keywords: Antibacterial activity; Lactoferricin; Mastitis; Synthetic peptide; Trueperella pyogenes
Mesh:
Substances:
Year: 2020 PMID: 33097042 PMCID: PMC7585202 DOI: 10.1186/s12917-020-02620-z
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Fig. 1Molecular structures for bLfcin and its derivatives. The molecular structures of (a) bLfcin, (b) bLfcin DB, and (c) bLfcin C36G are shown here. The dashed ellipses show the difference between the mercaptomethyl of bLfcin and the hydrogen base of bLfcin C36G
Synthetic peptides tested for antibacterial activity
| Peptides | Amino acid sequences (N-terminal to C-terminal) | Length (AA) | Molecular weight | Purity(%) |
|---|---|---|---|---|
| bLfcin | FKCRRWQWRMKKLGAPSITCVRRAF | 25 | 3125.82 | > 95 |
| bLfcin DB | FKCRRWQWRMKKLGAPSITCVRRAF (with a disulfide bond)a | 25 | 3123.82 | > 95 |
| bLfcin C36G | FKCRRWQWRMKKLGAPSITGVRRAFb | 25 | 3079.73 | > 95 |
aThe cysteines forming a disulfide bond are shadowed; bthe glycine mutation from the cysteine is boxed
Fig. 2CD spectra curves and secondary structure percentages of bLfcin and its derivatives. The peptides were detected in H2O (a), PBS (b), PBS with 0.56 mM SDS (c), and PBS with 8.33 mM SDS (d) solution. The CD spectra curves and the secondary structure percentages are indicated on the left and right, respectively
Antibacterial activity of the designed synthetic peptides against T. pyogenes and E. coli
| Strain | Antibacterial index | Lfcin | Lfcin DB | Lfcin C36G |
|---|---|---|---|---|
isolate | MIC50 | 3.9 (1.2) | 3.9 (1.2) | 7.8 (2.5) |
| MIC90 | 7.8 (2.5) | 3.9 (1.2) | 15.6 (5.0) | |
| MBC | 7.8 (2.5) | 3.9 (1.2) | 15.6 (5.0) | |
ATCC 19,411 | MIC50 | 3.9 (1.2) | 3.9 (1.2) | 7.8 (2.5) |
| MIC90 | 3.9 (2.5) | 3.9 (1.2) | 7.8 (5.0) | |
| MBC | 7.8 (2.5) | 3.9 (1.2) | 15.6 (5.0) | |
ATCC 25,922 | MIC50 | 62.5 (20.0) | 125.0 (40.0) | 125.0 (40.6) |
| MIC90 | 62.5 (20.0) | 250.0 (80.0) | 125.0 (40.6) | |
| MBC | 62.5 (20.0) | 250.0 (80.0) | 125.0 (40.6) |
Note: The MIC50 and MIC90 represent the concentrations required to inhibit 50 and 90% of the strains, respectively; MIC50, MIC90, and MBC in µg/mL (µM)
Fig. 3Time-kill curve of the peptides. T. pyogenes isolates (a), T. pyogenes ATCC 19411 (b), and E. coli ATCC 25922 (c) were co-incubated with bLfcin, bLfcin DB, and bLfcin C36G respectively at MBC of bLfcin (7.8 μg/mL for T.pyogenes, 62.5 μg/mL for E.coli). Y-axis represents the logarithm of CFU. X-axis represents the time point after incubation with peptides. The control is given by bacteria without peptide. Data point are shown by the mean ± standard deviation derived from three repeated experiments